Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy
Introduction: The full impact of COVID-19 infections on patients with cancer who are actively being treated with chemotherapy or immune checkpoint inhibitors (ICIs) has not been fully defined. Our goal was to track clinical outcomes in this specific patient population. Methods: We performed a retros...
Main Authors: | Haris Hatic, Kristine R. Hearld, Devika Das, Jessy Deshane |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/23/5954 |
Similar Items
-
Immune checkpoint inhibitors in cancer patients with COVID-19
by: Pan Yun, et al.
Published: (2023-07-01) -
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
by: Tomonari Kinoshita, et al.
Published: (2021-09-01) -
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
Short review of immunotherapy toxicity
by: Ivana Canjko, et al.
Published: (2021-01-01) -
Immune Targeted Therapies for COVID-19 Infection: A Narrative Review
by: Bahareh Forouzani-Haghighi, et al.
Published: (2022-07-01)